EVERSANA’s Post

What’s in Store for 2024? Three CEOs Look Ahead and Look Back on “Close to the Edge” https://ow.ly/WPPZ50Qmb8E From the approval of Alzheimer’s disease drug Leqembi to Carl Icahn’s battle over Illumina to the first CRISPR-edited therapy being approved, 2023 had more than its share of milestones shaping drug discovery, development, clinical trials, and commercialization. To look back at the year that is ending, and look ahead to 2024, GEN invited CEOs of three companies to offer some valuable perspective on the biopharma industry’s strengths and challenges, and the strengths and challenges of their own companies. • Neil McFarlane, CEO of Zevra Therapeutics • Karen Zaderej, CEO of axogen • Simon Arkell OLY, CEO of Ryght

Happy New Year! As a quick reminder, I am a Co-founder at DatAnon, the Data Anonymization company. The last year was exciting, as we built out our technology to handle many different data types and use cases. We anonymize data via geometrical transformations, so that it can be jointly analyzed. We provide products and services for: 1) Identifying patient responders in Clinical Trials 2) Improving treatment outcomes, particularly in oncology I'll be posting about our technology, use cases, results and more this year. Together with our partners, we hope to help #pharma companies get more drugs to market, and to the right patients. #clinicalresearch, #precisionmedicine, #drugdiscovery, #oncology, #pharmaceuticals

Thoughts on this? >> Gilead pays $43M to license Xilio’s IL-12 program that could turn ‘cold’ tumors ‘hot’ >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #productmarketing #pharma #healthcare

Biotech and pharma companies - How do we determine the most efficient regulatory path for codeveloped companion diagnostic tests (CDx)? A CDx can significantly maximize return on investment in clinical trials, but transitioning from a research-grade to a clinical-grade assay can present resource management challenges, especially for emerging companies. Regulatory experts Mwango Kashoki and Sinan Sarac share how to minimize time and resources in our New Medicines, Novel Insights Oncology report: #PrecisionOncology #Regulatory #NovelInsights

🚀 Every drug has a unique story, and Keytruda’s journey is particularly remarkable. 💊✨Keytruda (Pembrolizumab) has become the world’s top-selling drug, achieving an impressive $25 billion in sales in 2023. Its path from discovery to clinical trials and market dominance offers a masterclass in successful drug development. 📍 Key Highlights of Keytruda's Success: 1️⃣ Staggering Revenue: Reached $25 billion, accounting for about 42% of Merck's total revenue. 2️⃣ Serendipitous Discovery: Its discovery was an unexpected but fortuitous event. 3️⃣ Competitive Drive: Pressure from Bristol-Myers Squibb inspired Merck to aggressively push Keytruda in the market. 4️⃣ Strategic Investment: With significant financial backing, Merck utilized three years to continually update clinical data and execute a robust global marketing strategy focused on patient needs. 5️⃣ Collaborative Efforts: Partnerships and combination therapies have extended Keytruda's impact and longevity. 💡 While the discovery of a drug can be serendipitous, building a blockbuster like Keytruda requires strategic financial support and insightful clinical development. We provide a one-page cheatsheet to help you know the story of Keytruda. For details, please find it https://lnkd.in/g8jBQPXk 💊✨#Every drug tells a story #DrugWonder #Merck #Forbes #Oncology #Immunotherapy #FierceBiotech #Nature Reviews Drug Discovery

💡 Get all our latest company updates, with deep dives on the pivotal news shaping the dynamic landscape of oncology drug development, by subscribing to our mailing list today: https://buff.ly/44VVVTw #PYC #Biotech #Pharma #DrugDevelopment

Biotech and pharma companies - How do we determine the most efficient regulatory path for codeveloped companion diagnostic tests (CDx)? A CDx can significantly maximize return on investment in clinical trials, but transitioning from a research-grade to a clinical-grade assay can present resource management challenges, especially for emerging companies. Regulatory experts Mwango Kashoki and Sinan Sarac share how to minimize time and resources in our New Medicines, Novel Insights Oncology report: https://lnkd.in/eDJ7B7Nx #PrecisionOncology #Regulatory #NovelInsights

Biotech and pharma companies - How do we determine the most efficient regulatory path for codeveloped companion diagnostic tests (CDx)? A CDx can significantly maximize return on investment in clinical trials, but transitioning from a research-grade to a clinical-grade assay can present resource management challenges, especially for emerging companies. Regulatory experts Mwango Kashoki and Sinan Sarac share how to minimize time and resources in our New Medicines, Novel Insights Oncology report: https://lnkd.in/eYHpRUxA #PrecisionOncology #Regulatory #NovelInsights

Biotech and pharma companies - How do we determine the most efficient regulatory path for codeveloped companion diagnostic tests (CDx)? A CDx can significantly maximize return on investment in clinical trials, but transitioning from a research-grade to a clinical-grade assay can present resource management challenges, especially for emerging companies. Regulatory experts Mwango Kashoki and Sinan Sarac share how to minimize time and resources in our New Medicines, Novel Insights Oncology report: https://lnkd.in/e-iG-67V #PrecisionOncology #Regulatory #NovelInsights

Biotech and pharma companies - How do we determine the most efficient regulatory path for codeveloped companion diagnostic tests (CDx)? A CDx can significantly maximize return on investment in clinical trials, but transitioning from a research-grade to a clinical-grade assay can present resource management challenges, especially for emerging companies. Regulatory experts Mwango Kashoki and Sinan Sarac share how to minimize time and resources in our New Medicines, Novel Insights Oncology report: https://lnkd.in/gq6UNRdQ #PrecisionOncology #Regulatory #NovelInsights